Form 4: Sutro Biopharma Officer's RSU Vesting & Tax Withholding

Sutro Biopharma's Chief Administrative Officer, David Pauling, reported the vesting of 675 Restricted Stock Units and the subsequent withholding of 277 shares for tax obligations.

Summary

• David Pauling, Chief Administrative Officer and General Counsel of Sutro Biopharma, Inc. (STRO), reported transactions on March 4, 2026.
• 675 Restricted Stock Units (RSUs) vested, converting into 675 shares of Common Stock.
• 277 shares of Common Stock were withheld by the Issuer at a price of $21.31 per share to satisfy income tax withholding obligations related to the RSU settlement.
• The net effect of these transactions increased Pauling's direct beneficial ownership of Common Stock by 398 shares (675 acquired 277 disposed for tax).
• Following these transactions, Pauling directly beneficially owns 9,748 shares of Common Stock.
• The RSUs vested as part of an annual schedule, with the first tranche vesting on March 4, 2023.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax compliance. It neither signals significant positive nor negative developments for the company.

Positives

• The vesting of Restricted Stock Units indicates continued compensation and retention of a key executive, David Pauling.
• The increase in direct beneficial ownership of Common Stock by 398 shares (net of tax withholding) aligns the executive's interests with shareholders.

Negatives

• No specific negative events are indicated by this routine compensation-related transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and tax-related share withholding, are common in the biopharmaceutical industry as part of executive compensation packages. These events typically reflect pre-scheduled compensation plans rather than discretionary trading decisions, and are generally not indicative of broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine compensation event. It confirms continued executive alignment through equity ownership.
• Employees: No direct impact on general employees, but it reflects the company's executive compensation structure.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax withholding. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement.

Keywords

Sutro Biopharma, STRO, Form 4, Insider Transaction, David Pauling, RSU Vesting, Stock Compensation, Tax Withholding, Beneficial Ownership